Strand Genomics Changes Corporate Identity to Strand Life Sciences,
Launches in Silico ADMET Tool

BANGALORE, India, Sept. 1, 2005 - Strand Genomics, announced today
that it has changed its corporate identity to Strand Life Sciences,
effective immediately. It also announced the launch of its in silico
predictive ADMET tool, admetis. Strand Life Sciences website is
www.strandls.com and admetis website is www.admetis.com.

Strand has leveraged its core technologies to develop decision-
support solutions for powering drug discovery including in silico
predictive models for drug properties such as ADME and
Cardiotoxicity. In addition, Strand has an ongoing research program
in predictive modeling for hepatotoxicity. Strand partners with
discovery contract research companies in India to combine in silico
with wet lab techniques to offer consulting services starting from
compound design to lead generation.

"The change in corporate identity reflects the expanding focus of
the company. Our portfolio of products now extends beyond functional
genomics into computational chemistry.," said Vijay Chandru, CEO and
Chairman, Strand Life Sciences. "admetis addresses a key need in the
industry and can help profile compounds early."

admetis is a comprehensive tool for modeling and predicting drug-
relevant properties of molecules in silico. It gives users the power
to build custom models from scratch using their own data. This is
made possible through easy and intuitive model-building workflows
based on Strand's expertise in in silico model building. admetis
comes packaged with its pre-built models, truPK and truTox, for
predicting Bioavailability, Protein binding, Volume distribution,
Elimination half life, Rate of absorption and hERG binding. admetis
has an extensive data mining and visualization module that supports
an embedded chemical structure viewer.

"admetis couples pre-built models with a workflow-based modeling
platform making it a distinct offering." said Kas Subramanian, CSO,
Strand Life Sciences. "admetis is a highly intuitive and easy to use
tool that helps build accurate predictive models on the fly."

About Strand Life Sciences Pvt Ltd

Strand Life Sciences is a premier in silico technologies innovation
company, focused on drug discovery and development. Strand has over
the last five years, developed outstanding technologies and
capabilities in data analytics and predictive modeling in drug
discovery and development. Strand has built in-silico predictive
models for drug properties like ADME, Cardiotoxicity and has an
ongoing research program in predictive modeling for hepatotoxicity.
Strand has also developed tools for oligo design, microarray image
analysis and has executed several customer specific data analysis
projects. Strand partners with discovery contract research companies
in India to combine in silico and wet lab techniques to offer
consulting services starting from compound design to lead generation.

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech